Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income from Continuing Operations (2020 - 2025)

Silence Therapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 77909000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 533.3% to 77909000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1067000.0, a 102.08% increase, with the full-year FY2025 number at 1067000.0, up 102.35% from a year prior.
  • Income from Continuing Operations hit 77909000.0 in Q4 2025 for Silence Therapeutics, up from 20958000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for SLN hit a ceiling of 77909000.0 in Q4 2025 and a floor of 39184294.42 in Q3 2024.
  • Historically, Income from Continuing Operations has averaged 11708068.9 across 5 years, with a median of 16008730.05 in 2021.
  • The widest YoY moves for Income from Continuing Operations: up 533.3% in 2025, down 1134.0% in 2025.
  • Tracing SLN's Income from Continuing Operations over 5 years: stood at 15134115.09 in 2021, then decreased by 16.64% to 17652571.23 in 2022, then fell by 5.23% to 18575079.12 in 2023, then soared by 166.23% to 12302000.0 in 2024, then skyrocketed by 533.3% to 77909000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SLN at 77909000.0 in Q4 2025, 20958000.0 in Q3 2025, and 27354000.0 in Q2 2025.